Radius Health, Inc. (RDUS): Price and Financial Metrics
Today's Latest Price: $16.08 USD
Nov 27 1:00pm Add RDUS to Watchlist Sign Up
RDUS Stock Summary Radius Health Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than only 4.14% of US listed stocks. Equity multiplier, or assets relative to shareholders' equity, comes in at -2.37 for Radius Health Inc; that's greater than it is for just 4.61% of US stocks. Revenue growth over the past 12 months for Radius Health Inc comes in at 52.24%, a number that bests 90.26% of the US stocks we're tracking. Stocks that are quantitatively similar to RDUS, based on their financial statements, market capitalization, and price volatility, are LJPC, KPTI, VERU, ATNX, and QUIK. Visit RDUS's SEC page to see the company's official filings. To visit the company's web site, go to www.radiuspharm.com.
RDUS Price/Volume Stats
Radius Health, Inc. (RDUS) Company Bio
Radius Health is a biopharmaceutical company focused on developing new therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases including hormone responsive metastatic breast cancer. The company was founded in 2003 and is based in Waltham, Massachusetts.
RDUS Latest News Stream
All News Types
Commentary Corp. News Cramer Debt Offering Downgrade Earnings Hedge Fund Insider Buying Mgmt Change New Coverage (Bullish) New Coverage (Neutral) Options Product News PT Lowered PT Raised PT Set (Bearish) PT Set (Bullish) Rating Reiterated (Bearish) Rating Reiterated (Bullish) Rating Reiterated (Neutral) Resumes Coverage (Neutral) Rumor Stock Offering
Loading, please wait...
Latest RDUS News From Around the Web
Below are the latest news stories about Radius Health Inc that investors may wish to consider to help them evaluate RDUS as an investment opportunity.
Radius Health (RDUS) down 4% in premarket, has divested its second oncology pipeline asset, RAD140 to Ellipses Pharma, completing Radius’s divestment of its oncology assets.Under the agreement, Ellipses Pharma will take over the clinical development and commercialization of the drug candidate, and Radius will be entitled to receive royalties on the program...
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 28) 10X Genomics Inc (NASDAQ: TXG ) Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) Beigene Ltd (NASDAQ: BGNE ) Cardiff Oncology Inc (NASDAQ: CRDF ) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) Evogene Ltd (NASDAQ: EVGN ) Fate Therapeutics Inc (NASDAQ: FATE ) Guardant Health Inc (NASDAQ: GH ) InVitae Corp (NYSE: NVTA ) Kaleido Biosciences Inc (NASDAQ: KLDO ) Kura Oncology Inc (NASDAQ: KURA ) Lantern Pharma Inc. (NASDAQ: LTRN ) Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA ) Pacific Biosciences of California Inc (NASDAQ: PACB ) Prelude Therapeutics Incorporated (NASDAQ: PRLD ) (listed Thursday) Seattle Genetics, Inc. (NASDAQ: SGEN ) Shockwave Medical Inc...
Target enrollment milestone reached in the Phase 3 EMERALD studyLife cycle planning advancing in parallel with current Phase 3 monotherapy program …
WALTHAM, Mass., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS) today announced its participation in the following conferences…
The following slide deck was published by Radius Health, Inc. in conjunction with their 2020 Q2 earnings call....
Read More 'RDUS' Stories Here
RDUS Price Returns
Get Free Updates
Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!
Page generated in 0.8207 seconds.